Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A three-part, randomized, placebo-controlled, pharmacokinetic and safety trial of multiple doses of oral CR 845 in hemodialysis patients

Next Previous
Trial Profile

A three-part, randomized, placebo-controlled, pharmacokinetic and safety trial of multiple doses of oral CR 845 in hemodialysis patients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Difelikefalin (Primary) ; Difelikefalin
  • Indications Pruritus
  • Focus Pharmacokinetics

Most Recent Events

  • 12 Jul 2017 Status changed from recruiting to completed as per Cara Therapeutics media release
  • 12 Jul 2017 According to a Cara Therapeutics media release, the data from this trial will help to initiate a clinical trial of an oral CR845 pruritus in the non-dialysis CKD-associated pruritus patients in 2017.
  • 12 Jul 2017 Top line results are published in the Cara Therapeutics Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top